Dante Beccaria - Sanofi ADR Global VP
| SNY Stock | USD 47.98 0.20 0.42% |
Insider
Dante Beccaria is Global VP of Sanofi ADR
| Address | 46, avenue de la Grande Armée,, Paris, France, 75017 |
| Phone | 33 1 53 77 40 00 |
| Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0416 % which means that on every $100 spent on assets, it made $0.0416 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0582 %, implying that it generated $0.0582 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.13 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.14 in 2024, whereas Total Assets are likely to drop slightly above 88.7 B in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sally Jackson | GlaxoSmithKline PLC ADR | 52 | |
| Thomas Schinecker | Roche Holding Ltd | 48 | |
| Gonzalo Vina | AstraZeneca PLC ADR | N/A | |
| Elaine Sorg | AbbVie Inc | 54 | |
| Paul Penepent | Novartis AG ADR | N/A | |
| A Washington | Johnson Johnson | 70 | |
| Jennifer Mauer | Merck Company | N/A | |
| Deborah Eldracher | AstraZeneca PLC ADR | 59 | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| D Davis | Johnson Johnson | 69 | |
| Mathai Mammen | Johnson Johnson | 53 | |
| Claudia Bockstiegel | Roche Holding Ltd | 59 | |
| Lisa LeCointeCephas | Merck Company | 42 | |
| Sarah EltonFarr | GlaxoSmithKline PLC ADR | N/A | |
| Johannes MD | Roche Holding Ltd | 66 | |
| Dirk Brinckman | Johnson Johnson | N/A | |
| Azita Gerhardt | AbbVie Inc | 57 | |
| Robert Kowalski | Novartis AG ADR | 53 | |
| Julie Brown | GlaxoSmithKline PLC ADR | 62 | |
| Patrice Bula | Novartis AG ADR | 65 | |
| Jonathan Symonds | GlaxoSmithKline PLC ADR | 62 | |
Management Performance
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0416 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roy Papatheodorou, Executive Counsel | ||
| FranoisXavier Roger, Chief Officer | ||
| Paul Hudson, CEO Director | ||
| Madeleine Roach, Executive Operations | ||
| Pierre Chancel, Senior Marketing | ||
| Bruno Mnard, Chief officer | ||
| Dante Beccaria, Global VP | ||
| Thomas Larsen, Head Relations | ||
| Eva SchaeferJansen, Head Relations | ||
| JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
| Josephine Fubara, Chief Care | ||
| Laurent Gilhodes, Principal Accounting | ||
| Natalie Bickford, Executive Officer | ||
| Josep Catlla, Head Communications |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0416 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 138.72 B | ||||
| Shares Outstanding | 2.51 B | ||||
| Shares Owned By Institutions | 11.64 % | ||||
| Number Of Shares Shorted | 8.12 M | ||||
| Price To Earning | 7.78 X | ||||
| Price To Book | 1.55 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.